Herndon Capital Management’s Myriad Genetics MYGN Stock Holding History

Herndon Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$3K	Buy	+132	New	+$2.8K	﹤0.01%	190

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Herndon Capital Management's MYGN Position: Q2 2017 in Review

Herndon Capital Management opened a new position in Myriad Genetics (MYGN) in Q2 2017: 132 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #190 among its holdings.

239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

Herndon Capital Management held 132 shares of Myriad Genetics worth $3K as of Q2 2017.
Myriad Genetics was a new Herndon Capital Management position in Q2 2017.
Myriad Genetics made up ﹤0.01% of Herndon Capital Management's portfolio in Q2 2017, its #190 holding.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Herndon Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.